Defining the clinical course of multiple sclerosis: the 2013 revisions.
暂无分享,去创建一个
Jeffrey A. Cohen | S. Reingold | A. Thompson | F. Barkhof | C. Pozzilli | M. Sormani | X. Montalban | L. Kappos | C. Polman | P. Calabresi | G. Comi | B. Banwell | M. Freedman | F. Lublin | Aaron E Miller | P. Sørensen | E. Waubant | J. Wolinsky | M. Inglese | R. Rudick | G. Cutter | R. Fox | J. Petkau | A. Goodman | L. Balcer | B. Kieseier | P. O'Connor | M. Clanet | B. Bebo | J. Lincoln | C. Lubetzki | O. Stüve | J. Cohen | A. Thompson | A. Thompson | Jeffrey A. Cohen
[1] Hans Lassmann,et al. Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.
[2] M. Battaglini,et al. Cortical lesions in radiologically isolated syndrome , 2011, Neurology.
[3] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[4] D. Goodin,et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome , 2011, Neurology.
[5] J. Stockman. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2011 .
[6] L. Kappos,et al. Measuring disability in relapsing-remitting MS , 2010, Neurology.
[7] P. Calabresi,et al. Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for Neurodegeneration , 2010, Neurotherapeutics.
[8] F. Barkhof,et al. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis , 2010, Neuroradiology.
[9] P. Rieckmann,et al. The natural history of primary progressive multiple sclerosis , 2009, Neurology.
[10] F. Moore. INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME , 2009, Neurology.
[11] F Fazekas,et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[12] O. Kantarci,et al. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease , 2009, Multiple sclerosis.
[13] Lucien Rumbach,et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. , 2009, Archives of neurology.
[14] F. Barkhof,et al. Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. , 2009, Neuroimaging clinics of North America.
[15] Jeffrey A. Cohen,et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach , 2008, Multiple sclerosis.
[16] D. Bourdette,et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.
[17] Hans Lassmann,et al. The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.
[18] J. De Keyser,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[19] H P Hartung,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[20] S. Vukusic,et al. Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.
[21] Edmus Coordinating. Natural history of multiple sclerosis: A unifying concept , 2006 .
[22] G. Cutter,et al. MRI as a marker for disease heterogeneity in multiple sclerosis , 2005, Neurology.
[23] A J Thompson,et al. Is inflammation important in early PPMS? a longitudinal MRI study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[24] A. Thompson,et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.
[25] Marco Rovaris,et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.
[26] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[27] À. Rovira,et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[28] A. Thompson,et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.
[29] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[30] W. I. McDonald,et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis , 1996, Neurology.
[31] W. I. McDonald,et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.
[32] D. Miller,et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.
[33] A. Thompson,et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.